Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)
Completed · Phase 1/Phase 2
Conditions studied: Leukemia
In brief
The purpose of the study is to determine the safety and tolerability of the combination of BMS-833923 plus dasatinib in patients with chronic myeloid leukemia.
Key facts
- Study ID
- NCT01218477
- Run by
- Bristol-Myers Squibb
- People needed
- 33
- Starts
- 2011-01-01
- Expected to finish
- 2013-04-01
- Last updated by the study team
- 2016-06-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University Of California Medical Center — San Francisco, California, United States
- Sidney Kimmel Cancer Center At Johns Hopkins — Baltimore, Maryland, United States
- Ut M.D. Anderson Cancer Center — Houston, Texas, United States
- Local Institution — Hamilton, Ontario, Canada
- Local Institution — Toronto, Ontario, Canada
- Local Institution — Helsinki, Finland
- Local Institution — Bordeaux, France
- Local Institution — Poitiers, France
- Local Institution — Frankfurt am Main, Germany
- Local Institution — Bologna, Italy
- Local Institution — Orbassano(To), Italy
- Local Institution — Glasgow, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.